- Global Pharma News & Resources

Global Periodic Paralysis Treatment Market 2020 Detail Analysis focusing on Key Players like Strongbridge Biopharma plc, Sun Pharmaceutical Industries Ltd, Heritage, Mylan N.V., Zydus Cadila

Global Periodic Paralysis Treatment Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Global Periodic Paralysis Treatment Market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Global Periodic Paralysis Treatment Market report includes the market overviews, market strategies of each vendor in the market  and also the understanding about the market forces and how those can be exploited to create future opportunities. The Global Periodic Paralysis Treatment Market report studies present as well as future aspects of the Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis. The industry-changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users. Global Periodic Paralysis Treatment Market is growing at a steady CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth. A few of the major competitors currently working in the Global Periodic Paralysis Treatment Market are Strongbridge Biopharma plc, Sun Pharmaceutical Industries Ltd, Heritage, Mylan N.V., Zydus Cadila, Alembic Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd, X-GEN Pharmaceuticals, Inc, and others.

Get Sample Report + All Related Graphs & Charts @

Global Periodic Paralysis Treatment Market By Types (Hypokalemic Periodic Paralysis, Hyperkalemic Periodic Paralysis, Thyrotoxic Periodic Paralysis, Andersen-Tawil Syndrome), Drugs (Beta-Blockers, Carbonic Anhydrase Inhibitor and Others), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retailers and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Market Definition:

Periodic Paralysis is a rare inherited neuromuscular disorders characterized by occasional episodes of muscle weakness, stiffness or paralysis. These attacks can last for few seconds to few days depending on their type. It occurs when there is defect in the electrical-chemical communications between nerve cells and skeletal muscles when this occurs skeletal muscles are unable to respond to nerve signals resulting in temporary weakness or paralytic attacks.

According to the statistics published in the American Association of Neuromuscular & Electro diagnostic Medicine, it is estimated 3 in every 200,000 people are affected by primary periodic paralysis. It affects both male and female equally. Increased access to novel treatment options for conditions that previously have been untreated or treated by traditional medications and therapies and high finance in research and development are the key factors for market growth.

Market Drivers

Lack of physical activity and adoption of unhealthy lifestyle is driving the market growthJoint ventures by pharmaceuticals companies for the advancement of treatment is boosting the market growthHigh specific demand of novel treatment is accelerating the market growthHuge financial support to the researchers for developing novel intervention is enhancing the market growth

Market Restraints

Limited availability of medicinal treatment options due to low prevalence of periodic paralysis is restraining the market growthFewer approvals of drugs from the regulatory authorities is hindering the market growthLack of trained personnel and stringent safety regulations is hampering the market growth

 Grab Your Report at an Impressive 30% Discount! Please click Here@


By Types

Hypokalemic Periodic ParalysisHyperkalemic Periodic ParalysisThyrotoxic Periodic ParalysisAndersen-Tawil Syndrome

By Drugs

Beta-BlockersPropranololCarbonic Anhydrase InhibitorAcetazolamideDichlorphenamideOthers

By End Users

HospitalsHomecareSpecialty ClinicsOthers

By Distribution Channel

Hospital PharmacyOnline PharmacyRetailersOthers

By Geography

North AmericaSouth AmericaEuropeAsia-PacificMiddle East & Africa

Key Developments in the Market:

In December 2016, Strongbridge Biopharma plc has acquired U.S. commercialization rights for Keveyis from Taro Pharmaceutical Industries Ltd (a subsidiary of Sun Pharmaceutical Industries Ltd) for the treatment of periodic paralysis. Under the terms of agreement, Taro Pharmaceutical Industries Ltd to receive an upfront payment of USD 8.50 mm and is also eligible to receive additional future payments upon the achievement of certain sales unit milestones. The acquisition of U.S. rights expands company’s rare disease portfolio to include neuromuscular diseases.

In August 2015, Taro Pharmaceutical Industries Ltd received approval from the FDA for Keveyis (dichlorphenamide), oral carbonic anhydrase inhibitor for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic, periodic paralysis, and related variants.  The FDA approval of Keveyis is most awaited, new, effective treatment option for many years to the patients suffering from periodic paralysis.

Reasons to Purchase this Report

Current and future of Global Periodic Paralysis Treatment Market outlook in the developed and emerging marketsThe segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast periodRegions/Countries that are expected to witness the fastest growth rates during the forecast periodThe latest developments, market shares, and strategies that are employed by the major market players

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475


This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at

Editor Details

Last Updated: 24-Mar-2020